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Background. The independent prognostic impact, as well as the possible causal role, of hyperhomocysteinemia (HHcy) in
coronary artery disease (CAD) is controversial. No previous study specifically has addressed the relationship between HHcy and
mortality after coronary artery bypass grafting (CABG) surgery. The aim of this study is to evaluate the prognostic impact of
HHcy after CABG surgery. Methodology and Principal Findings. We prospectively followed 350 patients who underwent
elective CABG between May 1996 and May 1999. At baseline, fasting total homocysteine (tHcy) levels were measured in all
participants, and a post-methionine loading (PML) test was performed in 77.7% of them (n=272). After a median follow-up of
58 months, 33 patients (9.4%) had died, 25 because of cardiovascular events. HHcy, defined by levels higher than the 90
th
percentile (25.2 mmol/L) of the population’s distribution, was significantly associated to total and cardiovascular mortality
(P=0.018 [log-rank test 5.57]; P=0.002 [log-rank test 9.76], respectively). The PML test had no prognostic value. After multiple
adjustment for other univariate predictors by Cox regression, including statin therapy (the most powerful predictor in uni-/
multivariate analyses), high-sensitivity C Reactive Protein (hs-CRP) levels, and all known major genetic (MTHFR 677CRT
polymorphism) and non-genetic (B-group vitamin status and renal function) tHcy determinants, HHcy remained an
independent prognostic factor for mortality (HRs: 5.02, 95% CIs 1.88 to 13.42, P=0.001). Conclusions. HHcy is an important
prognostic marker after CABG, independent of modern drug therapy and biomarkers.
Citation: Girelli D, Martinelli N, Olivieri O, Pizzolo F, Friso S, et al (2006) Hyperhomocysteinemia and Mortality after Coronary Artery Bypass
Grafting. PLoS ONE 1(1): e83. doi:10.1371/journal.pone.0000083
INTRODUCTION
Homocysteine is a sulphur-containing amino acid formed as a by-
product of methyl-transfer reactions in methionine metabolism [1].
Since proposed in 1969 by McCully [2], the association between
serum total homocysteine (tHcy) and coronary artery disease (CAD)
has been strongly corroborated by recent meta-analyses of
numerous epidemiological studies [3]. Nevertheless, the indepen-
dent prognostic impact of tHcy, as well as its causal role in CAD
pathogenesis, remain controversial. Pieces of evidence in favor
include basic research studies on animal models indicating that Hcy
causes endothelial dysfunction/damage, lipid peroxidation, and
accelerated thrombosis [reviewed in 4]. Studies on the common
677CRT polymorphism of the Methylentetrahydrofolate reductase
(MTHFR) gene, known to be associated with a moderate elevation
of tHcy, support a causal link between Hcy and atherosclerosis
through the so-called ‘‘Mendelian randomization’’ phenomenon
[5], though some Authors recently disagreed [6]. Critics also
emphasize the lack of evidence, from the randomized controlled
trials published so far [7–10], that lowering tHcy by folic acid-based
multivitamin therapy could prevent ‘‘hard’’ vascular outcomes.
Finally, it is frequently underscored that the stronger associations
between Hcy and vascular risk have been found in cross-sectional or
case-control studies rather than in prospective studies [3,11], which
are generally considered superior in supporting causation. Indeed,
results from epidemiological studies on cardiovascular patients are
often weakened by the wide clinical heterogeneity of the patients
enrolled, as well as that of the endpoint considered.
We endeavored to further evaluate tHcy as secondary risk
predictor by studying prospectively a selected homogeneous
population of patients undergoing coronary artery by pass grafting
(CABG), which remains a cornerstone of CAD therapy even in the
percutaneous coronary intervention (PCI) era [12]. Total and
cardiovascular mortality were considered as the endpoints.
METHODS
Study population
The Verona Heart Project is a study aimed to search for new risk
factors for CAD in a population of subjects with objective
angiographic documentation of their coronary vessels. Details
about the enrolment criteria have been described elsewhere [13].
In the present study we used data from a total of 353 consecutive
adult patients of both sexes, who underwent to CABG at the
Cardiosurgery Unit of Verona between May 1996 and May 1999.
Angiographic CAD was assessed by two cardiologists unaware that
the patients were to be included in the study. The majority of
patients (93.4%) had severe multi-vessel CAD (stenosis$50% of
the vessel diameter in two or three of the main coronary arteries).
All participants came from the same geographical area (Northern
Italy), with a similar socio-economic background. They were
Academic Editor: Thomas Zwaka, Baylor College of Medicine, United States of
America
Received October 18, 2006; Accepted November 9, 2006; Published December
20, 2006
Copyright:  2006 Girelli et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: Supported by grants from the Veneto Region, MIUR, and the Cariverona
Foundation, Verona, Italy.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: domenico.girelli@
univr.it
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e83enrolled at scheduled ambulatory evaluation few days before
elective CABG surgery. At that time, blood sampling and
a complete clinical history was collected, including the assessment
of classical cardiovascular risk factors. The diagnosis of previous
myocardial infarction was based on a thorough review of the
medical history, previous ECG, and enzyme documentation, and/
or based on the finding of typical sequelae of infarction on
ventricular angiography. Left ventricular ejection fraction (LVEF)
was estimated by ventriculography and/or echocardiography. To
avoid any bias in tHcy measurement, we enrolled only subjects
who were not treated with vitamin supplementation or drugs
interfering with tHcy levels (i.e., anticonvulsivants, methotrexate
and penicillamine) [13]. Similarly, none of the enrolled subjects
had any major systemic acute illness, including myocardial
infarction (MI), in the preceding 3 months. The study was
approved by the Ethical Committee of our Hospital. Informed
consent was obtained from all the patients after a full explanation
of the study.
Assessment of outcome
Subjects were followed until death or May 2004. Study subjects
status was determined by search of the national population
register, and by an ambulatory or telephone survey. Ascertainment
of mortality status was complete (100 percent). The date of death
was obtained from the National Population Register. The causes
of death were obtained from death certificates kept at the Italian
Institute of Statistics (ISTAT). Death from cardiovascular causes
was defined as death caused by CAD, heart failure, peripheral
vascular disease, or cerebrovascular disease. Three subjects died
peri-operatively (during hospitalization and/or within one month
from surgery), so that they were excluded from the survival
analysis.
Laboratory testing
Samples of venous blood were drawn from each subject after an
overnight fast. Serum lipids, other routine biochemical parameters
including creatinine, as well as plasma folate, vitamin B12, and the
MTHFR 677CRT polymorphism were determined as previously
described [13]. The four variable version of the Modification of
Diet in Renal Disease (MDRD) equation was used to estimate the
glomerular filtration rate (GFR) from serum creatinine levels.
Vitamin B6 was measured by high-pressure liquid chromatogra-
phy (HPLC) with fluorometric detection [14]. High-sensitivity C-
reactive protein (hs-CRP) was measured by particle-enhanced
nephelometric immunoassay (Dade-Behring Inc., Newark, DE).
For tHcy (which refers to the sum of homocysteine, homocystine,
and homocysteine-cysteine mixed disulfide, free and protein
bound), blood was collected into EDTA-containing vacuum tubes
and kept on ice and in the dark; plasma was separated within
90 minutes; tHcy levels were determined by HPLC with
fluorometric detection, as described [13,15]. In 272 subjects, after
the first blood sampling, a standardized methionine-loading test
was performed by administering orally L-methionine (100 mg/kg)
mixed with 200 ml of orange juice, together with a standardized
low-protein breakfast; blood was then collected 6 hours later for
the determination of the post-methionine loading (PML) tHcy
level.
Statistics
All the calculations were performed with SSPS 13.0 statistical
package (SPSS Inc., Chicago, IL). Distributions of continuous
variables in groups were expressed as means6standard deviation.
Logarithmic transformation was performed on all skewed
variables, including tHcy, folate, vitamin B12, vitamin B6 and
hs-CRP. Hence, geometric means with 95% confidence intervals
(CIs) are given for these variables. Quantitative data were assessed
using the Student’s t-test, or by ANOVA with Tukey’s post-hoc
test when appropriate. Associations between qualitative variables
were analyzed with the x
2 test. Correlations between quantitative
variables were assessed using Pearson’s correlation test. Significant
associations between tHcy levels and other continuous or
categorical variables, were assessed by multiple regression models
estimating R
2 and standardized b-coefficients. Categorical vari-
ables were used after transformation into binary variables (i.e. for
MTHFR 677CRT polymorphism we considered homozygosity
versus non-homozygosity for the T allele). Hyperhomocysteinemia
(HHcy) was defined by tHcy levels higher than the 90
th percentile
of population’s distribution, i.e. $25.2 mmol/l. Survival was
assessed by the Kaplan-Meier method (log-rank statistic) and
Cox regression. Kaplan-Meier methods were used for survival
plots. Multivariate Cox proportional hazards analyses were
performed considering sex, age, other tHcy determinants
(MTHFR genotype, B-vitamin levels, GFR), and all predictors
of mortality at univariate analyses, including drug therapy at
discharge. Final models were obtained by a backward stepwise
logistic regression approach, with P=0.10 as the critical value for
entering/excluding variables in the model. Hazard ratios (HRs)
and 95% CIs are reported with two-tailed probability values. A P
value less than 0.05 was used to indicate statistical significance.
RESULTS
Characteristics of the patients
Table 1 (left column) shows the complete clinical and biochemical
characteristics at baseline of the patient’s population (n=350) after
exclusion of peri-operative deaths (n=3; tHcy values: 18.6, 11.7,
and 11.4 mmol/l, respectively). The mean age of patients was
60.268.9 years, 82.9% were males, 61.8% had had a previous
MI, 93.4% had multi-vessel disease. They had a substantial
burden of traditional cardiovascular risk factors, such as smoking
(65.6%), hypertension (66.2%), and so on. Patients with HHcy
were similar to the others in age, sex, degree of CAD, history of
MI before CABG, drug therapy at discharge, and most other
traditional risk factors (Table 1, right columns). On the other
hand, HHcy patients had decreased GFR and B-vitamin levels,
while hs-CRP levels and homozygosity for the T allele of MTHFR
were increased. The PML increase of tHcy over basal levels (D
PML tHcy) was similar in the two groups.
Determinants of homocysteine levels
Fasting tHcy levels correlated positively with hs-CRP (r=0.143,
P=0.008), and negatively with levels of folate (r=20.330,
P,0.001), vitamin B12 (r=20.207, P,0.001), and estimated
GFR (r=20.226, P,0.001). The relations with vitamin B6 levels
(r=20.097, P=0.077) and with age (r=0.096, P=0.072) were
not significant. As expected, MTHFR 677TT subjects had
increased mean levels of tHcy (20.5 mmol/l, 95% CIs 17.8 to
23.5) as compared to either 677CT (15.5 mmol/l, 95% CIs 14.7 to
16.2) or 677CC (14.1 mmol/l, 95% CIs 13.2 to 15.0) subjects
(P,0.001 by ANOVA with Tukey post-hoc test). A multiple
regression model including all the above mentioned variables
showed folate, vitamin B12, GFR, and MTHFR TT homozygosity,
as independent predictors of tHcy levels (Table 2).
Mortality by baseline tHcy levels
After a median follow-up of 58 months (range 3 to 87), 33 patients
(9.4%) had died. Twenty-five deaths (75.8% of total deaths) were
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cardiovascular causes were mainly due to cancer (6), one patient
died from pneumonia, and one from undetermined cause (he had
moved to another country and died there, so that we could not
retrieve adequate information). The prevalence of HHcy was
significantly higher in total and cardiovascular mortality groups
(21.2% and 28.0%, respectively) as compared to survivors (8.8%;
P,0.05 by x
2-test in both cases). In HHcy patients, mortality was
nearly twice (20%) as much than in the others, and all deaths in
HHcy group were from cardiovascular causes (Table 1). The
univariate HRs of HHcy for total and cardiovascular mortality
were 2.64, 95% CIs 1.14 to 6.10 (P=0.023), and 3.67, 95% CIs
Table 1. Clinical and laboratory characteristics of patients by baseline tHcy (90
th percentile=25.2 mmol/l).
..................................................................................................................................................
Total population (n=350) tHcy,90
th percentile (n=315) tHcy$90
th percentile (n=35) P *
Age (years) 60.268.9 60.168.8 61.069.9 0.569
Male sex (%) 82.9 83.2 80.0 0.636
Number of stenosed vessels (%)
1 6.6 6.4 8.6 0.869
2 15.9 16.1 14.3 0.869
3 77.5 77.5 77.1 0.869
MI history (%) 61.8 61.3 65.7 0.614
History of smoke (%) 65.6 65.0 70.6 0.519
Hypertension (%) 66.2 66.2 65.7 0.950
Diabetes (%) 15.6 17.3 0 0.009
BMI (Kg/m
2) 26.763.3 26.763.3 25.962.8 0.136
Estimated GFR (ml/min)ˆ 72.6615.9 73.4615.2 65.0619.9 0.004
Cholesterol (mmol/l) 5.9261.10 5.9061.10 6.0961.03 0.340
LDL-Cholesterol (mmol/l) 3.9760.97 3.9760.99 3.9660.80 0.961
HDL-Cholesterol (mmol/l) 1.2260.32 1.2360.32 1.1960.33 0.595
Triglycerides (mmol/l) 2.0561.23 2.0361.24 2.2261.20 0.388
hs-CRP (mg/l) 2.54 (2.27–2.84) 2.44 (2.17–2.73) 3.68 (2.58–5.26) 0.026
Folate (nmol/l) 12.2 (11.7–12.8) 12.6 (12.0–13.3) 8.9 (7.8–10.2) ,0.001
Vitamin B12 (pmol/l) 283 (269–297) 288 (274–303) 235 (193–288) 0.017
Vitamin B6 (nmol/l) 33.0 (31.0–35.1) 33.5 (31.6–35.5) 29.2 (20.8–41.1) 0.200
tHcy (mmol/l)
{ 15.7 (15.0–16.3) 14.3 (13.9–14.8) 34.7 (31.0–38.8) ,0.001
PML-tHcy (mmol/l)
{ 41.8 (40.0–43.5) 39.4 (37.9–40.9) 67.9 (59.6–77.3) ,0.001
D PML-tHcy (mmol/l)
{ 24.7 (23.4–26.1) 24.3 (23.0–25.7) 28.4 (22.1–36.5) 0.092
MTHFR 677 genotype (%)
CC 31.1 33.9 5.8 ,0.001
TC 52.5 53.1 47.1 ,0.001
TT 16.4 13.0 47.1 ,0.001
LVEF
D (%)
$55 63.4 64.1 56.3 0.678
40–54 28.5 27.9 34.3 0.678
,40 8.1 8.0 9.4 0.678
Drug therapy at discharge
ACE-inhibitors (%) 48.1 48.7 42.9 0.510
b-blockers (%) 50.4 51.0 45.7 0.556
Antiplatelet therapy
1 (%) 92.3 92.0 94.3 0.637
Statins (%) 58.2 58.6 54.3 0.624
Deaths, n (%)
total 33 (9.4) 26 (8.3) 7 (20) 0.024
by cardiovascular cause 25 (7.3) 18 (5.9) 7 (20) 0.002
ˆ glomerular filtration rate (GFR) estimated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation.
{tHcy, total homocysteine; PML-tHcy, post methionine loading t-Hcy; PML-tHcy increase (i.e. the difference between PML-tHcy and tHcy); the data of PML-tHcy were
available for 272 subjects.
DLVEF, left ventricular ejection fraction
*values of P are calculated by t-test or x
2-test.
1Antiplatelet therapy included Aspirin (80.7%), Ticlopidine (10.8%), and Indobuphen (1.2%).
doi:10.1371/journal.pone.0000083.t001
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e831.53 to 8.76 (P=0.004), respectively. Figures 1A and 1C represent
the Kaplan-Meier survival plots for total and cardiovascular
mortality of HHcy patients as compared to the others (log-rank
statistic=5.57, P=0.018; and 9.76, P=0.002, respectively). Since
literature often consider a tHcy level of 15 mmol/l as the upper
limit beyond which the cardiovascular risk may start to increase
[1], we further stratified our population with tHcy,25.2 mmol/l
into two subgroups with (n=139) or without (n=176) baseline
tHcy levels$15 mmol/l. However, with respect to either total or
cardiovascular (Figures 1B and 1D) mortality, the group with tHcy
between 15 and 25.2 mmol/l behave similarly to the group with
tHcy ,15 mmol/l, and significantly different from that with
tHcy$25.2 mmol/l.
Other univariate predictors
Statin therapy at discharge was the most powerful prognostic
indicator (HRs for total and cardiovascular mortality=0.14, 95%
CIs 0.06 to 0.33; P,0.001; and 0.20, 95% CIs 0.08 to 0.50;
P=0.001). Other predictive factors in univariate analyses were hs-
CRP levels, age, LVEF, and b-blocker therapy at discharge.
Details about the relative HRs with 95% CIs are shown in
Table 3A, together with values adjusted for age and sex. The
MTHFR 677TT genotype was not significantly associated to an
increased mortality, while we observed a non significant trend
toward the contrary: for example, the prevalence of TT genotype
was only 6.3% in the total mortality group, 8.3% in the group died
for cardiovascular causes, as compared to 17.5% in survivors
(P=NS). Moreover, none of the other determinants of tHcy in the
multiple regression model (folate, vitamin B12) showed a predictive
value at a P level,0.10).
Multivariate predictive models
Table 3B shows the final multivariate Cox predictive models for
total and cardiovascular mortality, obtained by backward stepwise
logistic regression approach (P$0.10 to remove). All univariate
predictors of total or cardiovascular mortality with P,0.10
(Table 3A), including sex, history of myocardial infarction, and
all the significant predictors of tHcy (MTHFR genotype,
glomerular filtration rate, folate, and vitamin B12) were initially
entered. Statin therapy was confirmed as the most significant
protective predictor. Noteworthy, in multivariate models hs-CRP
levels were no longer independent predictors of either total or
cardiovascular mortality. Additional stepwise models revealed that
this loss of statistical significance was due to adjustment for statin
therapy (data not shown). On the contrary, HHcy remained
a significant independent predictor even after adjustment for all
potential confounders, including major tHcy determinants such as
GFR, folate, vitamin B12, and MTHFR 677 TT genotype
(Table 3B).
DISCUSSION
In this prospective study, hyperhomocysteinemia (.25.2 mmol/l)
was an important and independent prognostic factor of mortality
after CABG. A particular effort was made to take into account all
possible confounders, including the known major genetic (MTHFR
677CRT polymorphism) and non-genetic (renal function, B-group
vitamin status) determinants of tHcy, as well as modern drug
therapy. To put our results into perspective from a clinical
standpoint, we propose the following considerations.
Comparison with previous studies
Most of the prospective studies published so far on tHcy focused
on subjects without evident cardiovascular disease at entry,
yielding variable results [3,11]. Relatively few studies [16,17]
focused on patients with angiographically defined CAD, and none
of them specifically addressed the prognostic impact of tHcy after
CABG. Nygard et al. [16] evaluated mortality in 587 patients with
angiographically defined CAD, 318 of them submitted to CABG.
After a median follow-up of 4.6 years, they found in the entire
population a 10.9% total mortality, with a ratio of 4.5 for patients
with the highest (.20 mmol/l) compared to the lowest (,9 mmol/
l) tHcy values, after adjustment for traditional risk factors.
Anderson et al. [17] studied a total of 1,412 patients after
a median follow-up of 3 years from angiography (total deaths:
11.8%), subsequently treated by CABG, angioplasty, or medical
therapy alone. In the entire group, subjects with elevated tHcy
(mean level 22.9 mmol/l) had a significant mortality risk, but no
specific data were given for the CABG subgroup. Our results are
well in line with these studies, indicating HHcy as a prognostic
marker of mortality in high-risk CAD patients. Moreover, our
multivariate adjustment included newer prognostic factors like hs-
CRP, major genetic and non-genetic determinant of tHcy levels
(MTHFR 677CRT polymorphism, B group vitamins, renal
function), and details on current drug therapy after CABG. The
predictive value of tHcy remained statistically significant even after
correction for a major determinant of mortality such as statin
therapy.
The PML test has been suggested as an useful tool to uncover
subtle abnormalities of the homocysteine metabolic pathway [18].
In case-control studies, it was reported to identify up to an
additional 27% of potentially ‘‘at-risk’’ patients with normal fasting
tHcy levels [19]. In the routine clinical setting, however, the value
of the PML test has been defined ‘‘uncertain’’ by a recent expert
panel [20], which particularly underscored the lack of prospective
studies. To the best of our knowledge, this is the first prospective
study evaluating the prognostic impact of PML test in CAD
patients. Neither PML tHcy absolute values, nor the relative tHcy
increase, gave significant predictive information in addition to
fasting tHcy. Thus, our data suggest a little value of this
cumbersome procedure in the practical scenario.
MTHFR and risk
Despite being confirmed as a major independent predictor of
hyperhomocysteinemia, the MTHFR 677TT genotype was not at
all a predictor of mortality, even in univariate analysis. Meta-
analyses have quantified into ,2.5 mmol/l the usual mean increase
in tHcy levels of TT versus CC subjects at a population level [21].
As a consequence, several thousands of subjects need to be
Table 2. Predictors of tHcy levels (dependent variable) in
multiple linear regression analysis.
......................................................................
Independent variables standardized b-coefficient P
MTHFR genotype (677 TT) 0.293 ,0.001
Vitamin B12 2 0.287 ,0.001
GFR 2 0.283 ,0.001
Folate 2 0.252 ,0.001
hs-CRP 0.082 0.094
Sex (female) 2 0.045 0.396
Vitamin B6 0.027 0.591
Age 2 0.025 0.645
R
2=0.336, Adjusted R
2=0.318, P,0.001
doi:10.1371/journal.pone.0000083.t002
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present, may indicate a causal link between tHcy and CVD
because of the so-called ‘‘Mendelian Randomization’’ [22]. Our
study was clearly underpowered for such a purpose, this being
likely the main reason for the null finding. On the other hand, we
previously demonstrated in this population a substantial gene-
environment interaction, so that the MTHFR 677CRT poly-
morphism increased tHcy levels only in individuals with low folate
status, while it was neutral in individuals with adequate folate
levels [13]. Such an effect was confirmed by a recent meta-analysis
[5], revealing that the relation between the MTHFR genotypes and
CAD, if any exists, is a complex phenomenon whit marked inter-
individual variations. Thus, our null finding for MTHFR
genotypes and mortality is not at all surprising, and in line with
the reports from Anderson (mortality in MTHFR 677TT versus
677CC subjects=11.7% versus 15.1%, P=0.62) [17], and from
Figure 1. Kaplan-Meier survival plots for total mortality (A–B) and cardiovascular death (C–D) in relation to tHcy levels. Cutoff points for tHcy strata at
25.2 mmol/l in plots A and C, at 15 and 25.2 mmol/l in plots B and D.
doi:10.1371/journal.pone.0000083.g001
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e83others who observed divergent associations with incident CAD
when considering tHcy or the MTHFR 677CRT polymorphism
[23].
Other predictors of mortality in post-CABG patients
In this study, statin therapy was the most powerful independent
predictor of mortality (Relative Risk Reduction in fully adjusted
models: 76–85%). About 60% of our patients, recruited between
1996 and 1999, assumed statin therapy, which was formally
introduced as a recommendation into guidelines for CABG
surgery only in 1999 [24]. Our data are consistent with previous
observations in CABG patients [25]. High-sensitivity CRP,
recognized as an important predictor of cardiovascular events in
the past few years, was significantly associated to mortality in
univariate, and age/sex adjusted, analyses. However, statistical
significance was no longer evident after adjustment for statin
therapy. This probably reflect the recently highlighted CRP-
lowering effect of statins, in a manner largely independent of LDL
cholesterol levels [26].
tHcy and risk: pathopysiological considerations
The association between hyperhomocysteinemia and mortality
after CABG represents a clue, but not a proof, of causality.
Recently, large randomized trials showed no clinical benefit of
tHcy-lowering by means of B-group vitamins in secondary
prevention [9,10]. Of note, however, they enrolled patients
irrespective of their baseline tHcy levels, that were generally low
(means: 12.2 to 13.2 mmol/l). On the other hand, in our study
a well-defined detrimental role of tHcy was evident only for
relatively high levels (.25 mmol/l), consistent with those with the
highest predictive value on mortality in previous studies on
patients with established CAD (see above) [16,17]. Accordingly,
experimental studies on endothelial function in humans suggest
that the toxicity of tHcy may be barely discernible at levels only
slightly elevated [27]. These considerations may indicate the need
of focusing future trials with tHcy-lowering therapy on CAD
subjects with more than a slight hyperhomocysteinemia. Neverthe-
less, it is increasingly recognized that therapy with B-group
vitamins interferes with complex phenomena, such as nucleic acid
synthesis and DNA methylation [27,28], suggesting caution, as
well as the need of alternative approaches [29].
Study strength and limitations
A limitation of this study lies on the relatively low number of
events. It also implies the limitations of nonrandomized observa-
tional studies (i.e., unsuspected selection biases and confounding),
and possible inaccuracy in assigning causes of death by certificates.
Nevertheless, it has some advantages. First, the clinical homoge-
neity of the sample (post-CABG patients with advanced athero-
sclerosis), which, on the other hand, may well represent the real
world. Indeed, in terms of age, and burden of classical risk factors
(see table 1), our patients fit the typical profile of CAD patients that
are seen by cardiologists and cardiosurgeons in daily practice. A
second point of strength is the robustness of the endpoint
considered, i.e. mortality. By contrast with these points, previous
prospective studies on tHcy often included a larger number of
CAD patients, but with a wide clinical heterogeneity (different
degree of CAD, age at disease onset, interventional or medical
therapy), as well as with artificially combined outcomes (cardio-
vascular ‘‘events’’, angiographic restenosis, and so on). Further
potential advantages of this study are the full adjustment for
modern medical treatment and predictors, as well as, for genetic
and non-genetic determinants of tHcy, and the absence of
Table 3A. Univariate and sex/age adjusted predictors of total and cardiovascular mortality by Cox regression analyses.
..................................................................................................................................................
Total mortality Cardiovascular mortality
Variable Univariate* Age and sex adjusted Univariate* Age and sex adjusted
HR P HR P HR P HR P
Hcy (ln) 1.82 (0.84–3.91) 0.127 1.74 (0.78–3.90) 0.178 2.79 (1.27–6.10) 0.011 2.80 (1.23–6.36) 0.014
Hhcy (tHcy$25.2 mmol/l) 2.64 (1.14–6.10) 0.023 2.59 (1.12–5.99) 0.027 3.67 (1.53–8.76) 0.004 3.60 (1.50–8.62) 0.004
Statin therapy (no/yes) 0.14 (0.06–0.33) ,0.001 0.15 (0.06–0.38) ,0.001 0.20 (0.08–0.50) 0.001 0.22 (0.09–0.56) 0.001
b-blocker therapy (no/yes) 0.49 (0.24–1.00) 0.05 0.54 (0.26–1.12) 0.100 0.47 (0.20–1.08) 0.07 0.51 (0.22–1.20) 0.123
hs-CRP (ln) 1.57 (1.14–2.16) 0.006 1.51 (1.11–2.05) 0.009 1.48 (1.01–2.15) 0.042 1.40 (0.98–2.02) 0.068
age (10 years increment) 1.58 (1.04–2.41) 0.034 1.74 (1.12–2.70) 0.013
# 1.61 (0.99–2.62) 0.054 1.72 (1.04–2.86) 0.036
#
LVEF,40%
1 3.08 (1.12–8.49) 0.030 3.04 (1.10–8.39) 0.032 3.05 (0.98–9.45) 0.054 3.01 (0.97–9.37) 0.057
*Cox regression was used, with entering of only 1 variable. The following clinical variables were tested: age (10 years increment), male sex, number of coronary vessels
diseased, history of myocardial infarction, history of smoking, hypertension, diabetes, BMI and medical therapy at discharge (ACE-inhibitors, b-blockers, aspirin, statin).
The following laboratory variables were tested: GFR (10 ml/min increment), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, hs-CRP (ln), folate (ln),
vitamin B12 (ln), vitamin B6 (ln), Hcy (ln), HHcy (tHcy$25.2 mmol/l) , PML-tHcy (ln), DPML-tHcy (ln) and MTHFR genotype (677 TT homozygosity). Only univariate
predictors with at least one P value#0.07 are shown in the table.
#sex adjusted
1LVEF, left ventricular ejection fraction; as compared with the group with normal left ventricular function, i.e. LVFE$55%
doi:10.1371/journal.pone.0000083.t003
Table 3B. Final Cox predictive models of total and
cardiovascular mortality.
......................................................................
Total mortality Cardiovascular mortality
HR P HR P
Hhcy
(tHcy$25.2 mmol/l)
5.02
(1.88–13.42)
0.001 7.07
(2.49–20.07)
,0.001
Statin therapy
(no/yes)
0.12
(0.04–0.34)
,0.001 0.18
(0.06–0.53)
0.002
Multivariate Cox predictive model involves backward stepwise logistic
regression (P$0.10 to remove). All univariate predictors of total or
cardiovascular mortality with P,0.10 (Table 3A), including sex, history of
myocardial infarction, and also all the significant predictors of tHcy (GFR, MTHFR
genotype, folate, and vitamin B12) were initially entered.
doi:10.1371/journal.pone.0000083.t004
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PLoS ONE | www.plosone.org 6 December 2006 | Issue 1 | e83confounding from vitamin supplementation. As mentioned above,
nowadays the prognostic impact of tHcy may become hard to
evaluate in populations such as those from Northern America,
where (differently from Europe) folic acid fortification of grain
products issued by FDA in 1996 has been demonstrated to
effectively reduce tHcy levels [30].
Conclusions
Irrespective of causality, hyperhomocysteinemia appears as
a prognostic marker of mortality after CABG. Its effect was
independent of the most significant predictor, which was
represented by the lipid-lowering, and probably anti-inflammato-
ry, therapy with statins. Measuring tHcy before CABG may help
to identify a high-risk subgroup of patients for whom it may be
especially important to follow a healthy lifestyle and diet, as well as
to receive optimal treatments for known causal risk factors.
Further studies with adequate design are needed to clarify whether
or not patients with HHcy should take advantage from tHcy-
lowering therapy, as well as to identify the tHcy threshold level
that would be worth to treat, to reduce mortality after CABG.
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